1. Home
  2. SMBK vs ALLO Comparison

SMBK vs ALLO Comparison

Compare SMBK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SMBK
  • ALLO
  • Stock Information
  • Founded
  • SMBK N/A
  • ALLO 2017
  • Country
  • SMBK United States
  • ALLO United States
  • Employees
  • SMBK N/A
  • ALLO N/A
  • Industry
  • SMBK Major Banks
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SMBK Finance
  • ALLO Health Care
  • Exchange
  • SMBK Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • SMBK 611.7M
  • ALLO 677.5M
  • IPO Year
  • SMBK N/A
  • ALLO 2018
  • Fundamental
  • Price
  • SMBK $36.67
  • ALLO $2.20
  • Analyst Decision
  • SMBK Buy
  • ALLO Buy
  • Analyst Count
  • SMBK 5
  • ALLO 12
  • Target Price
  • SMBK $28.20
  • ALLO $10.06
  • AVG Volume (30 Days)
  • SMBK 63.5K
  • ALLO 2.6M
  • Earning Date
  • SMBK 10-21-2024
  • ALLO 11-07-2024
  • Dividend Yield
  • SMBK 0.87%
  • ALLO N/A
  • EPS Growth
  • SMBK N/A
  • ALLO N/A
  • EPS
  • SMBK 1.93
  • ALLO N/A
  • Revenue
  • SMBK $159,196,000.00
  • ALLO $43,000.00
  • Revenue This Year
  • SMBK N/A
  • ALLO N/A
  • Revenue Next Year
  • SMBK $12.25
  • ALLO $5,902.96
  • P/E Ratio
  • SMBK $19.03
  • ALLO N/A
  • Revenue Growth
  • SMBK 2.18
  • ALLO 26.47
  • 52 Week Low
  • SMBK $19.00
  • ALLO $1.99
  • 52 Week High
  • SMBK $37.72
  • ALLO $5.78
  • Technical
  • Relative Strength Index (RSI)
  • SMBK 68.41
  • ALLO 35.38
  • Support Level
  • SMBK $35.12
  • ALLO $1.99
  • Resistance Level
  • SMBK $36.58
  • ALLO $3.36
  • Average True Range (ATR)
  • SMBK 0.90
  • ALLO 0.20
  • MACD
  • SMBK -0.10
  • ALLO -0.09
  • Stochastic Oscillator
  • SMBK 79.61
  • ALLO 10.72

About SMBK SmartFinancial Inc.

SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: